Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

In other recent news, Palatin Technologies has completed the enrollment phase of its Phase 2 clinical trial for PL8177, a melanocortin-1 receptor agonist being tested for ulcerative colitis.

MC2-R is the only melanocortin receptor that does not respond to MSH peptides (Table 1). Thus MC2-R displays considerably greater ligand specificity than other members of this family. The ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may ... identifier NCT06565611. About Melanocortin 4 Receptor Agonists Effect on Obesity ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.